Market Spotlight: Irritable Bowel Syndrome (IBS)
Market Spotlight: Irritable Bowel Syndrome (IBS)
€1,241.16
This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were approximately 714.1 million prevalent cases of irritable bowel syndrome (IBS) in those aged 15 years and over worldwide, and forecasts that number to increase to 785.7 million prevalent cases by 2028.
- The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.
- Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route. High-impact upcoming events for drugs in the IBS space comprise topline Phase II trial results for ORP-101, topline Phase IIa trial results for vibegron, and an expected PDUFA date for Linzess.
- The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 19.8%, and the average probability a drug advances from Phase III is 67.6%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.7 years in the overall gastroenterology (non inflammatory bowel disease) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 65% of trials in Phase I–II, and only 35% in Phase III–IV.
- The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the IBS space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for IBS, with 50 trials.
- AbbVie leads industry sponsors with the highest overall number of clinical trials for IBS, followed by GlaxoSmithKline
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Laxatives
9 Antidiarrheal drugs
9 Antispasmodics
9 Antidepressants
9 Serotonin receptor agonists
10 Chloride channel activators
10 Guanylyl cyclase C agonists
10 Antibiotics
10 Opioid receptors
10 Probiotics
12 EPIDEMIOLOGY
18 MARKETED DRUGS
21 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Zelnorm for IBS (July 8, 2019)
27 Multiple Drugs for IBS (June 25, 2019)
28 Linzess for IBS (June 18, 2019)
30 IB-Stim for IBS (June 7, 2019)
32 KEY UPCOMING EVENTS
33 KEY REGULATORY EVENTS
33 Ardelyx Touts Ibsrela’s Novel Mechanism Of Action For IBS-C
33 FDA Approves The First Device To Treat Pain Caused By IBS
33 Poland Switches from Rx-To-OTC Mylan’s Duspatalin For IBS, Plus Orion’s ED Treatment
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
35 Sanofi Tapping AI To Help Consumers Manage IBS
35 Sanofi Personalizing IBS Treatment With Digital Therapy
35 AstraZeneca Acquires All Linzess Rights In China
35 Alfasigma Acquires Sloan’s Zelnorm
37 REVENUE OPPORTUNITY
38 CLINICAL TRIAL LANDSCAPE
39 Sponsors by status
40 Sponsors by phase
42 BIBLIOGRAPHY
43 Prescription information
44 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of IBS, 2019–28
17 Figure 2: Prevalent cases of IBS, by age group, 2019
21 Figure 3: Overview of pipeline drugs for IBS in the US
22 Figure 4: Pipeline drugs for IBS, by company
22 Figure 5: Pipeline drugs for IBS, by drug type
22 Figure 6: Pipeline drugs for IBS, by classification
30 Figure 7: Linzess for IBS (June 18, 2019): Phase IIIb – IBS-C Abdominal Symptoms
32 Figure 8: Key upcoming events in IBS
34 Figure 9: Probability of success in the IBS pipeline
38 Figure 10: Clinical trials in IBS
38 Figure 11: Top 10 drugs for clinical trials in IBS
39 Figure 12: Top 10 companies for clinical trials in IBS
39 Figure 13: Trial locations in IBS
40 Figure 14: IBS trials status
41 Figure 15: IBS trials sponsors, by phase
13 Table 1: Prevalent cases of IBS, 2019–28
LIST OF TABLES
15 Table 2: Prevalent cases of IBS, by gender, 2019
16 Table 3: Prevalence of IBS, by gender, 2019
19 Table 4: Marketed drugs for IBS
24 Table 5: Pipeline drugs for IBS in the US
27 Table 6: Zelnorm for IBS (July 8, 2019)
28 Table 7: Multiple Drugs for IBS (June 25, 2019)
29 Table 8: Linzess for IBS (June 18, 2019)
30 Table 9: IB-Stim for IBS (June 7, 2019)
37 Table 10: Historical global sales, by drug ($m), 2015–19
37 Table 11: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Thyroid Cancer 
Sign up to the